Lisvy®

Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch

Description: One patch applied once per week for three weeks (21 days) followed by one week without patch per cycle. Each patch contains 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Transdermal

Duration Type: Short-acting

Duration: One week

Regimen:
  • weekly (3 weeks on, 1 week without patch)

Dose: 0.02mg EE and 0.05mg gestodene per day

Active Pharmaceutical Ingredient (API):
  • ethinyl estradiol
  • gestodene

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.

Project Phase: Limited Market Availability

Development Stage: SRA/WHO PQ Approved

Active Development: Yes

Status Details:
  • This patch was approved in the EU in 2014 and was outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry occurred in late 2015, under the name Lisvy®.
  • Product was withdrawn in October 2016 over concerns about the results of a stability test run by Bayer.

Additional Information

References:

Vertical Tabs

Print